Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma
暂无分享,去创建一个
S. Pignata | B. Daniele | G. Signoriello | M. Di Maio | C. Gallo | F. Perrone | E. De Maio | A. Annunziata
[1] P. Rougier,et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Stockler,et al. Use of tamoxifen in advanced‐stage hepatocellular carcinoma , 2005, Cancer.
[3] J. Llovet,et al. Updated treatment approach to hepatocellular carcinoma , 2005, Journal of Gastroenterology.
[4] A. Burroughs,et al. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. , 2004, The Lancet. Oncology.
[5] K. Soo,et al. High‐dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial , 2002, Hepatology.
[6] S. Pignata,et al. Hepatocellular Carcinoma: Systemic Treatments , 2002, Journal of clinical gastroenterology.
[7] S. Pignata,et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. , 2002, Current pharmaceutical design.
[8] S. Assmann,et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.
[9] F. Izzo,et al. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.
[10] S. Pignata,et al. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial , 1998, The Lancet.
[11] Wolfgang Greiner,et al. Health Technology Assessment (HTA) , 2008 .
[12] O. Seror,et al. Local/regional and systemic treatments of hepatocellular carcinoma. , 2005, Seminars in liver disease.
[13] T. Peters,et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.
[14] Bellia Mario,et al. Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) , 2000 .